With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable.

Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event dedicated to harnessing the full power of proteomics across drug discovery pipelines. Designed for scientific innovators like you, explore how next-generation proteomic platforms are accelerating understanding of pathology, unveiling novel drug targets, and transforming hit-to-lead development.

With a special focus on optimizing proteomics instruments to balance throughput and sensitivity, automating sample processing, unveiling hidden disease mechanisms with PTM analysis, and defining gold-standard analysis methodologies; this forum is ideal for proteomics leaders aiming to expand the druggable proteome and achieve therapeutic options for diseases with unmet need.

As proteomics continues to evolve, make headlines, and revolutionize therapeutic development, unite with 70+ Directors, Vice President and Experts in Proteomics, Chemical Biology, Mass Spectrometry and Bioinformatics to achieve protein level insights to advance your own discovery pipeline.